AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Transplantation, AutologousBone Marrow TransplantationHematopoietic Stem Cell TransplantationStem Cell TransplantationTransplantation, HomologousTransplantation ConditioningPeripheral Blood Stem Cell TransplantationMultiple MyelomaMelphalanBone MarrowLiver TransplantationGraft vs Host DiseaseCombined Modality TherapyTreatment OutcomeRemission InductionBone Marrow CellsWhole-Body IrradiationAntineoplastic Combined Chemotherapy ProtocolsGraft SurvivalRecurrenceBone Marrow PurgingKidney TransplantationCyclophosphamideSalvage TherapyLymphoma, Non-HodgkinStem CellsDisease-Free SurvivalBusulfanHematopoietic Stem Cell MobilizationHematopoietic Stem CellsEtoposideHodgkin DiseaseCarmustineHematologic NeoplasmsTransplantation ChimeraCytarabineTissue DonorsMyeloablative AgonistsSurvival RateRetrospective StudiesSurvival AnalysisHeart TransplantationVincristineAntigens, CD34Time FactorsCell TransplantationLung TransplantationLeukemiaHistocompatibility TestingFollow-Up StudiesThiotepaImmunosuppressive AgentsGranulocyte Colony-Stimulating FactorGraft RejectionPrognosisLeukemia, Myeloid, AcuteTransplantation, IsogeneicHistocompatibilityAnemia, AplasticTransplantation ImmunologyOrgan TransplantationCord Blood Stem Cell TransplantationLeukapheresisDexamethasoneHematopoiesisMesenchymal Stem Cell TransplantationLymphomaMyelodysplastic SyndromesAmyloidosisLymphoma, Mantle-CellPrednisoneAntineoplastic Agents, AlkylatingBone and BonesDoxorubicinThalidomideAntibodies, Monoclonal, Murine-DerivedNeoplasm, ResidualBoronic AcidsPyrazinesLymphoma, FollicularIslets of Langerhans TransplantationImmunosuppressionTransplantationPancreas TransplantationLeukemia, MyeloidAcute DiseasePodophyllotoxinCell DifferentiationGraft vs Tumor EffectAutograftsHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesLymphoma, T-Cell, PeripheralLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHLA AntigensAntineoplastic AgentsProspective StudiesMice, Inbred C57BLAntibodies, Monoclonal
Multiple myelomaHaematopoietic stem cell transplantHSCTTransplantsASCTPeripheral blood stemTherapiesIntraventricular TransplantationDiffuse large B-MurinePatient's own cellsHigh-doseColony-stimulDiseaseReconstitutionCyclophosphamideMyelomaSurvivalLymphomaImmunologySolid tumorsOutcomesTumorTumorsImmuneProliferation2000ProcedureBlood stem cellsGVHDClinicalRemissionNeutrophil recoveryRelapseMesenchymal stromal cellsTreatmentsDonor cellsUmbilicalLymphomasHaematologicalPluripotent stemTreatmentDifferentiationKnee osteoarthritis10.1038AllogenicStromal cellsGrafts
Multiple myeloma20
Haematopoietic stem cell transplant1
HSCT15
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • this is used in both autologous and allogenic HSCT. (bdbiosciences.com)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
  • The ability to correct genetic hematopoietic diseases by gene therapy has a number of advantages over current therapies that involve allogeneic hematopoietic stem cell transplantation (HSCT). (nih.gov)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
  • The biological questions with MonoMAC center around whether the individual leukocyte compartments that are lost in MonoMAC (B-lymphocytes, NK cells, and monocytes) will be constituted with HSCT, and whether the residual recipient T-lymphocytes will represent an impediment to engraftment. (nih.gov)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • Non-myeloablative autologous hemopoietic stem-cell transplantation (HSCT) shows some promise in treating scleroderma. (mountsinai.org)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • HSCT patients are presumed immunocompetent if they are at least 24 months post-HSCT, are not receiving immunosuppressive therapy, and do not have graft- versus-host disease (GVHD). (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
Transplants13
  • Conditions like bone marrow transplants or stem cells were difficult to get treated. (gomedii.com)
  • We know that Bone marrow transplants can help solve many problems. (gomedii.com)
  • When stem cell transplants were first developed, the new stem cells came from bone marrow, and so this was known as a bone marrow transplant. (gomedii.com)
  • To understand the different types of stem cell transplants and how they work, we spoke with Borje S. Andersson, M.D., Ph.D. Here's what he had to say. (mdanderson.org)
  • What are the types of stem cell transplants? (mdanderson.org)
  • Stem cell transplants fall into two categories: autologous and allogeneic. (mdanderson.org)
  • At the time they performed the first transplants surprisingly little was known about hematopoietic stem cells, immune responses to transplants or the complex human leucocyte antigen system. (revistadehematologia.org.mx)
  • Firstly, precisely these haematopoietic progenitors are key in autologous and allogeneic transplants, but not in CAR-T therapies. (mdanderson.es)
  • Outcomes among patients with blood and marrow transplants have improved, thanks to better donor-recipient matching (such as through human leukocyte antigen typing), improved patient support systems, and less toxic treatment regimens, says Devine, who is also senior vice president and senior medical director of research operation at the Center for International Blood and Marrow Transplant Research. (managedhealthcareexecutive.com)
  • One big improvement has occurred in the realm of allogeneic transplants (in which donor cells are used). (managedhealthcareexecutive.com)
  • We've managed to be able to reduce the rates of severe graft-versus-host disease-that's the major complication of transplants," says Devine. (managedhealthcareexecutive.com)
  • There are many clinical trials in the cellular therapies space outside of bone marrow transplants, such as CAR-T cell therapy and the use of NK cells, says Ronneberg, noting that a few CAR-T therapies have already received FDA approval. (managedhealthcareexecutive.com)
  • The idea to use transplants of dopa- ment of protocols that allow generation of fully functional mine-producing cells to substitute for the lost midbrain and safe midbrain dopamine neurons from stem cells. (lu.se)
ASCT4
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Much of the curative potential of allografts is attributed to the graft-versus-tumor (GvT) response that aims to destroy residual tumor cells that persist after induction therapy and ASCT [ 5 ]. (biomedcentral.com)
  • The implication of these results would be that myeloma-specific T cell subfamilies might be positively selected from the donor inoculum and infused to myeloma patients post ASCT, to afford separation of allo- from tumor-reactive T cells without the prior need to define specific target antigens. (biomedcentral.com)
  • 2 The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 study showed that patients receiving an autologous SCT (ASCT) followed by an allo-SCT had significantly higher CR rates that patients receiving double ASCTs. (medicalupdateonline.com)
Peripheral blood stem6
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Now, stem cells are more often collected from blood (a peripheral blood stem cell transplant). (gomedii.com)
  • Anastasia A, Giglio F, Mazza R, Sarina B, Todisco E, Bramanti S, Castagna L. Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. (gitmo.it)
  • Thirty patients (20 males and 10 females), who were candidates for autologous peripheral blood stem cell transplantation, were included in the study. (ogu.edu.tr)
Therapies5
  • CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. (bmj.com)
  • Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. (gitmo.it)
  • In addition, the activation of haematopoiesis after antitumoral therapies could increase bone marrow FDG uptake diffusely. (hindawi.com)
  • In these therapies, what we need are T lymphocytes, which are processed in the laboratory and manipulated after their extraction so that they develop antitumoral activity against the disease suffered by each specific person ," explains Dr de la Fuente. (mdanderson.es)
  • Other promising developments to improve outcomes in allo-SCT include conditioning with radiolabelled anti-CD66, as well as salvage therapy with daratumumab 8 or newer imids which suggest that allo-SCT has the potential to enhance the efficacy of other therapies that may have been less effective pre-transplantation. (medicalupdateonline.com)
Intraventricular Transplantation1
Diffuse large B-7
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Three separate cohorts of patients (with diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma) received buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent. (haematologica.org)
  • Overall, 72 patients (26 with diffuse large B-cell lymphoma, 22 with mantle cell lymphoma, and 24 with follicular lymphoma) were treated. (haematologica.org)
  • two patients (one each with diffuse large B-cell lymphoma and mantle cell lymphoma) achieved a complete response. (haematologica.org)
  • Malignant blast cells (i.e. diffuse large B-cell lymphoma) are fast-growing and result in aggressive disease, whereas malignant mature lymphocytes (i.e. follicular lymphoma) behave indolently. (oncolink.org)
  • Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. (canceropole-est.org)
  • Clinically, grade 3B follicular lymphoma is treated like diffuse large B-cell lymphoma . (medscape.com)
Murine4
Patient's own cells2
High-dose12
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • In a stem cell transplant, the patient gets high-dose of chemotherapy. (gomedii.com)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
  • Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • We evaluated hematopoietic stem cells according to CD34 expression and aldehyde dehydrogenase (ALDH) activity in peripheral blood and apheresis product samples from patients after mobilization with granulocyte-colony-stimulating factor (G-CSF) alone or G-CSF after high-dose cyclophosphamide (4 g/m(2) once daily, intravenously on day 1). (ogu.edu.tr)
Colony-stimul1
  • 3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
Disease29
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • Thomas has been diagnosed with sickle cell disease which affects the red blood cells and needs an urgent Stem cell transplant but it was not available in his country. (gomedii.com)
  • This is called graft-versus-host disease. (mdanderson.org)
  • Results Using the 5TGM1-Kalw/RijHSD immunocompetent in vivo model we have demonstrated that reovirus reduces both MM tumor burden and myeloma-induced bone disease. (bmj.com)
  • Chemotherapeutic agents, corticosteroids, and monoclonal antibodies are used to reduce the disease burden, and bisphosphonates are used to promote bone healing and to provide secondary prophylaxis against skeletal-related events (eg, hypercalcemia, bone fracture, spinal cord compression, need for radiation, and need for surgery). (medscape.com)
  • A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease. (dukecancerinstitute.org)
  • If you received bone marrow from someone else, you may develop signs of graft-versus-host disease ( GVHD ). (medlineplus.gov)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. (harvard.edu)
  • For this research we are using the genetic disease, canine leukocyte adhesion deficiency (CLAD), as a model for applying advances in understanding of stem cell biology to enhance gene transfer into the hematopoietic stem cells. (nih.gov)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
  • Therapeutic regeneration of molecularly engineered and transplanted autologous stem cells in neurological and cardiovascular diseases due to inability of self-regeneration or repair of endogenous stem cells at sites of inflammation or disease at various stages of progress for regeneration of the damaged tissue depending upon the sites and nature of degeneration. (hoajonline.com)
  • Cancer stem cellsand their susceptibility over their expected to be "downstream or progeny" cancer cells represent a target for therapeutic interventions to prevent latency and consequently relapse or metastasis of the malignant disease. (hoajonline.com)
  • Transient activation of CD4+ CD25+ T regulatory cells is required for autoimmune disease containment since their chronic activation leads to deleterious self-tolerance and infection or disease reactivation or tumour development as well as occurrences of relapse. (hoajonline.com)
  • Gene delivery through stem cells using specific viral vectors are also utilised to confer lineage specificity of transducedautologous or allogeneic stem cell gene expressionin the recipient while addressing graft versus host disease. (hoajonline.com)
  • Adoptive Allogeneic T-cell therapy (ATCT) might be curative for MM, however current ATCT protocols often lead to graft versus host disease (GvHD). (biomedcentral.com)
  • By then infusing the animals with B10.D2 T cells from only the TCR Vβ 2, 3 and 8.3 families appropriately pre-activated in vitro, we saw a vigorous GvM response without any clinical or histological signs of GvHD or disease relapse, which translated into long-term, disease-free survival. (biomedcentral.com)
  • The nature of disease (indolent vs. aggressive) is correlated to the stage of lymphocytic differentiation of the malignant cells. (oncolink.org)
  • Breast cancer, a common cancer in women, is a disease in which cancer (malignant) cells are found in the tissues of the breast. (stopgettingsick.com)
  • It is these donor cells that, once infused into the patient, will populate the bone marrow and rebuild the immune system, which is called the graft-versus-disease effect ," highlights this specialist. (mdanderson.es)
  • Symptoms related to bone marrow dysfunction, such as anemia, leukopenia, or thrombocytopenia, are rare at presentation but can also be observed in the later stages of the disease. (medscape.com)
  • 3. Cancer is not the only disease benefited by transplantation. (managedhealthcareexecutive.com)
  • There are increasing indications not only for patients with cancer, but also for nonmalignant conditions like sickle cell disease and even potentially down the road, autoimmune diseases like multiple sclerosis," says Devine. (managedhealthcareexecutive.com)
  • 7 In the recently completed LenaRIC study patients undergoing allo-SCT with reduced-intensity conditioning received lenalidomide for 12 months from day 35 post-transplantation, with DLI for mixed chimerism or persistent disease. (medicalupdateonline.com)
  • Graft-versus-host disease of the gut and liver was suspected. (cdc.gov)
  • Over the next 10 days, despite treatment with broad- fl udarabine and cyclophosphamide), followed by spectrum antimicrobial drugs and corticosteroids, the prophylaxis against graft-versus-host disease (alemtuzumab patient had intermittent fever, continued elevation of liver and cyclosporine). (cdc.gov)
  • Cell Replacement Therapy for Parkinson's Disease - Evaluating the potential of autologous grafting. (lu.se)
  • Cell Therapy for Parkinsons Disease: What Next? (lu.se)
Reconstitution2
Cyclophosphamide3
Myeloma8
  • Before the transplant, drug treatment is used to reduce the number of myeloma cells in the patient's body. (gomedii.com)
  • RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect. (dukecancerinstitute.org)
  • Transplanting only tumor reactive donor T cells that mediate a graft-versus-myeloma (GvM) but not GvHD may overcome this problem. (biomedcentral.com)
  • Pre-stimulation ex vivo of allogeneic T cells by exposure to MOPC315.BM MM cells in the presence of IL-2, anti-CD3 and anti-CD28 resulted in expansion of the myeloma-reactive T cell TCRVβ 2, 3 and 8.3 subfamilies. (biomedcentral.com)
  • Repeated infusion of naïve myeloma-reactive T cell TCRVβ 2, 3 and 8.3 subfamilies was also effective. (biomedcentral.com)
  • To test this rationale, we used the allogeneic B10.D2 → Balb/c BMT model with MOPC315.BM myeloma cells. (biomedcentral.com)
  • Bone marrow transplant is becoming a safer choice for elderly patients with lymphoma, myeloma, acute leukemia, and myeloid dysplastic syndrome, says Devine. (managedhealthcareexecutive.com)
  • The efficacy of allo-SCT in MM relies on the transplanted immune system having an anti-tumour effect on the host bone marrow, the so-called graft-versus-myeloma (GvM) effect. (medicalupdateonline.com)
Survival5
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
  • These data demonstrate that a transplantation protocol involving only selective tumor-reactive donor T cell families is an effective immunotherapy and results in long-term survival in a mouse model of human MM. The results highlight the need to develop similar ATCT strategies for MM patients that result in enhanced survival without symptoms of GvHD. (biomedcentral.com)
  • Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. (cdc.gov)
Lymphoma7
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • 211At conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. (fredhutch.org)
  • Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. (canceropole-est.org)
  • Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry. (canceropole-est.org)
  • Because the chromosomal t(14;18) translocation is found in the majority of patients with follicular lymphoma, bone marrow aspiration and chromosome analysis can also help establish the diagnosis. (medscape.com)
  • Most patients with follicular lymphoma present at an advanced stage, and most patients have bone marrow involvement at diagnosis. (medscape.com)
Immunology2
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
Solid tumors1
Outcomes4
  • In the early twentieth century, Ernest Amory Codman, a Boston surgeon, argued strongly for the formal study of surgical outcomes in an effort to understand which surgeons, hospitals, and surgical procedures produced good versus bad outcomes (Neuhauser, 2002). (nationalacademies.org)
  • 5 Combining rituximab, a monoclonal antibody targeting the CD20 antigen on B cells, with standard chemotherapy has improved NHL treatment outcomes. (haematologica.org)
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
  • Immunoselected STRO-3+ mesenchymal precursor cells reduce inflammation and improve clinical outcomes in a large animal model of monoarthritis. (sciendo.com)
Tumor10
  • Healthcare providers call this "graft-versus-tumor" effect (GVT). (clevelandclinic.org)
  • Moreover, increased effector-memory CD8 + T cells correlated with decreased tumor burden. (bmj.com)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Our emerging clinical data demonstrates that these gene-modified T cells are very active in killing tumor cells initially, but they lose their ability to function within a few weeks. (ca.gov)
  • Tumors contain a minority population of cancer stem cells that maintain the tumor. (hoajonline.com)
  • In marked contrast to the cancer stem cells, the tumor cells without "stemness" have either no capacity or a markedly diminished capacity, to form new tumors. (hoajonline.com)
  • The tumor will rapidly recur if the therapy eliminates cancer cells but spares a significant population of the cancer stem cells. (hoajonline.com)
  • Since GvT responses involve T-cell recognition of tumor-specific peptides presented by MHC molecules [ 14 ], it may be possible to identify and select donor T cells that provide beneficial GvT responses but minimal GvHD risk. (biomedcentral.com)
  • In this regard, immune-transcriptome analyses of T cell receptor (TCR) Vβ CDR3-size and sequence is being used to characterize alloreactive versus tumor-specific T-cell responses. (biomedcentral.com)
  • Tissue from the tumor needs to be taken to the laboratory for estrogen and progesterone tests at the time of biopsy because it may be hard to get enough cancer cells later, although newer techniques can be used on tissue that is not fresh. (stopgettingsick.com)
Tumors3
  • While the origin of these tumors is still not definitively known, the two theories with the most support suggest that these tumors arise from a primitive cell derived either from an embryologic tissue called the neural crest, or from resident cells in the body (called mesenchymal stem cells) that have a capability to become one of a variety of tissue types. (sarcomahelp.org)
  • Tumors in the Ewing's family of sarcomas are made of primitive cells, which are cells that haven't yet decided what type of cell they are. (sarcomahelp.org)
  • On the other hand, elimination or escape of Treg cells also causes the reactivation and induction of tumors and relapse. (hoajonline.com)
Immune14
  • This is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. (clevelandclinic.org)
  • The transplanted cells kill any remaining cancer cells and restore the patient's immune system. (mdanderson.org)
  • Conclusion These data highlight the importance of reovirus-induced immunotherapy for targeting MM cells within the BM niche and suggest that combination with agents which boost antitumor immune responses should be a priority. (bmj.com)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
  • 1957). This pioneering work laid the foundation for the exploration of hematopoietic stem cells and their role in treating diseases of the blood and immune system. (revistadehematologia.org.mx)
  • A strategy in the treatment of cancer by harnessing the immune system, called adoptive cell therapy, is to use an individual's own immune cells (T cells) and genetically modify them to target them to kill the cancer. (ca.gov)
  • The purpose of the current study is to give gene-modified T cells in combination with gene-modified stem cells to reprogram the immune system to recognize and kill cancer cells that have the NY-ESO-1 protein with sustained killing activity. (ca.gov)
  • Gene modification of cells involves the transfer of foreign genetic material (DNA) into a cell, in this case the immune system cells and stem cells. (ca.gov)
  • This process will endow the recipient immune cells and descendants of the stem cells with the ability to eliminate cancer cells that express the cancer specific protein, NY-ESO-1. (ca.gov)
  • The specific receptor against cancer cells that will be transferred to the immune cells and stem cells is called NY-ESO-1 T cell receptor (or TCR). (ca.gov)
  • In this study, the gene-modified immune cells will be given in combination with the gene-modified stem cells. (ca.gov)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • The fundamental problem here is that the graft-versus-host effect, that is, the infused cells and the new immune system, reject the patient. (mdanderson.es)
  • In autologous transplantation the tool is chemotherapy, in allogeneic transplantation it is the new immune system and in CAR-T cell therapy it is the patient's own re-educated T-lymphocytes ," concludes this expert. (mdanderson.es)
Proliferation3
20001
Procedure3
Blood stem cells3
GVHD1
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
Clinical6
  • This project represents a pre-clinical model for gene transfer into hematopoietic stem cells. (nih.gov)
  • The long-term objective is to develop strategies that will allow levels of expression of CD18 in hematopoietic cells of children with leukocyte adhesion deficiency (LAD) that are sufficient to reverse the clinical phenotype. (nih.gov)
  • The extension of bone marrow and extramedullary involvement should be carefully evaluated to establish prognosis and clinical management [ 4 ]. (hindawi.com)
  • Cryopreserved allogeneic mesenchymal stem cells enhance wound repair in full thickness skin wound model and cattle clinical teat injuries. (sciendo.com)
  • Also, the multidisciplinary coordination exercise needed to develop this clinical trial protocol will undoubtfully be useful to conduct academic clinical trials in the field of cell therapy in the near future. (unav.edu)
  • Methods: A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. (unav.edu)
Remission1
Neutrophil recovery3
  • We could not find a relationship between the transplanted SSClo CD45(dim) CD34(hi) cell dose or SSClo ALDH(br) cell dose and platelet or neutrophil recovery. (ogu.edu.tr)
  • The optimal thresholds for SSClo CD45(dim) CD34(hi) cells were 5.40 x 106/kg for neutrophil recovery and 7.22 x 106/kg for platelet recovery. (ogu.edu.tr)
  • The optimal thresholds for SSClo ALDH(br) cells were 6.53 x 106/kg for neutrophil recovery and 8.72 x 106/kg platelet recovery. (ogu.edu.tr)
Relapse1
Mesenchymal stromal cells3
  • Comparison of human mesenchymal stromal cells from four neonatal tissues: Amniotic membrane, chorionic membrane, placental decidua and umbilical cord. (sciendo.com)
  • The aim of this study is to evaluate the feasibility, safety, and efficacy of cell therapy based on mesenchymal stromal cells derived from adipose tissue intramuscular administration to patients with type 2 diabetes mellitus with critical limb ischemia and without possibility of revascularization. (unav.edu)
  • Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases. (unav.edu)
Treatments8
  • Healthcare providers typically recommend stem cell transplantation if initial treatments don't work or if conditions have come back. (clevelandclinic.org)
  • Providers may recommend allogeneic stem cell transplantation if initial treatments didn't work or treatments worked but the condition has come back. (clevelandclinic.org)
  • While both treatments help your bone marrow to develop new blood cells, studies show allogeneic stem cell transplantations work by causing the donor cells to attack unhealthy cells. (clevelandclinic.org)
  • Providers may use allogeneic stem cell transplantation if other treatments aren't successful. (clevelandclinic.org)
  • Some medical treatments may affect transplantation. (clevelandclinic.org)
  • This reduced differentiation of CD34+ hematopoietic progenitor stem cells could occur due to both infectious and non-communicable diseases and also due to their drug induced treatments. (hoajonline.com)
  • The best hope for regeneration of these permanently damaged cells is optic stem cell therapy combined with continued drug treatments or other exogenous biomaterial implants depending upon the relevant ophthalmological condition. (hoajonline.com)
  • However it is not possible to offer any guarantee about the effectiveness of any stored Cells for any treatments including those involving cell transplantation or that these Cells will provide any benefits to your child. (bioeden.com)
Donor cells2
  • Where do allogeneic stem cell transplant donor cells come from? (mdanderson.org)
  • If the donor cells aren't a close enough match, the patient's body may recognize the donor cells as foreign and reject them. (mdanderson.org)
Umbilical6
Lymphomas4
  • Pretargeted Radioimmunotherapy for B-cell Lymphomas. (fredhutch.org)
  • The belief that T-cell lymphomas have a worse prognosis than B-cell lymphomas remains controversial. (oncolink.org)
  • REAL/WHO- [6] - classification includes leukemias and lymphomas, with 3 categories based on lineage and morphology (Hodgkin, B cell, and T/NK cell). (oncolink.org)
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
Haematological1
  • 10 Data from the European Society for Blood and Marrow Transplantation (EBMT) megafile database indicates that the graft-versus-tumour effect achieved with allo-SCT is weaker and PFS rates lower in MM than in other types of haematological cancers. (medicalupdateonline.com)
Pluripotent stem3
Treatment15
  • For example, people who have stem cell transplantation go through intensive chemotherapy before treatment. (clevelandclinic.org)
  • Autologous Bone Marrow Treatment in India, is one of the most recent demands of many of our patients from Congo and the Middle east. (gomedii.com)
  • How is Autologous Bone Marrow Treatment in India done and what is the cost of Autologous Bone Marrow Treatment in India? (gomedii.com)
  • Bone marrow in general is an expensive affair, this is because the treatment is not provided everywhere. (gomedii.com)
  • Autologous Bone Marrow Treatment in India is an ideal one with one of the best oncologists for your treatment. (gomedii.com)
  • Thomas decided to travel to India where he will go through pre-treatment procedures of Blood tests and stem cell biopsy. (gomedii.com)
  • Bone marrow harvested progenitor cell treatment. (futuremedicalgroup.com)
  • The marrow is then placed into a centrifuge to extract the progenitor cells and growth factors that are then used for treatment. (futuremedicalgroup.com)
  • If you are interested in discussing if a Bone Marrow Harvested Progenitor Cell treatment may be right for you, please contact us for additional information. (futuremedicalgroup.com)
  • Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. (futuremedicalgroup.com)
  • A prospective multi-site registry study of a specific protocol of autologous bone marrow concentrate for the treatment of shoulder rotator cuff tears and osteoarthritis. (futuremedicalgroup.com)
  • 1992). Since then, hematopoietic stem cells, with their unique ability to differentiate into various blood cell types, have proven to be a revolutionary tool in the treatment of numerous hematological disorders. (revistadehematologia.org.mx)
  • Use of a chronic model of articular cartilage and meniscal injury for the assessment of long-term effects after autologous mesenchymal stromal cell treatment in Steep. (sciendo.com)
  • The chance of recovery (prognosis) and choice of treatment depend on the stage of the cancer (whether it is just in the breast or has spread to other places in the body), the type of breast cancer, certain characteristics of the cancer cells, and whether the cancer is found in the other breast. (stopgettingsick.com)
  • Ninety eligible patients will be randomly assigned at a ratio 1:1:1 to one of the following: control group (n = 30), low-cell dose treatment group (n = 30), and high-cell dose treatment group (n = 30). (unav.edu)
Differentiation1
  • 2017). MMP-2 and MMP-14 Silencing Inhibits VEGFR2 Cleavage and Induces the Differentiation of Porcine Adipose-Derived Mesenchymal Stem Cells to Endothelial Cells. (sciendo.com)
Knee osteoarthritis1
  • Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study. (sciendo.com)
10.10381
Allogenic1
  • Based on the report Thomas will either go through Allogenic (related Donor) or Autologous (healthy cells from their own body) donor selection. (gomedii.com)
Stromal cells2
  • Methods This study used human peripheral blood mononuclear cells from healthy donors and in vitro co-culture of MM cells and BM stromal cells to recapitulate the resistant BM niche. (bmj.com)
  • MM cells co-cultured with BM stromal cells displayed resistance to reovirus-induced oncolysis and bystander cytokine-killing but remained susceptible to killing by reovirus-activated NK cells and MM-specific cytotoxic T lymphocytes. (bmj.com)
Grafts2
  • Flow cytometric enumeration of CD34+ HSCs and progenitor cells is an established method for the evaluation of bone marrow and stem cell grafts. (bdbiosciences.com)
  • eg, bone, bone marrow, and skin grafts) Genetically identical (syngeneic [between monozygotic twins]) donor tissue (isografts) Genetically. (msdmanuals.com)